{"organizations": [], "uuid": "459f97a1aabd74b432a3b25567dde29a3e812be4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-6857/social", "site_section": "https://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "https://www.wsj.com/articles/how-big-biotech-can-win-back-investors-1523554441", "country": "US", "domain_rank": 387, "title": "How Big Biotech Can Win Back Investors", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.144, "site_type": "news", "published": "2018-04-12T21:34:00.000+03:00", "replies_count": 0, "uuid": "459f97a1aabd74b432a3b25567dde29a3e812be4"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/how-big-biotech-can-win-back-investors-1523554441", "ord_in_thread": 0, "title": "How Big Biotech Can Win Back Investors", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Big biotech stocks are trading at their lowest valuations in years, but don’t underestimate their ability to turn things around quickly.\nThe first-quarter earnings season, which starts next week, will highlight the struggles of the big players—weak growth and few new products. That contrasts with the industry’s smaller, more speculative players. The Nasdaq Biotechnology Index, which is weighted by market value, has returned about 9% over the past 12 months. An equal weight biotech index, which places greater emphasis on the... ", "external_links": [], "published": "2018-04-12T21:34:00.000+03:00", "crawled": "2018-04-12T22:54:50.023+03:00", "highlightTitle": ""}